Granted Patent
B2
US 12,378,312 · App. 18/153,643 · Granted Aug 5, 2025
Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof
Inventors:
Kalyani Mondal (San Mateo, CA); Betty Chan Li (Millbrae, CA); Yu Chen (Foster City, CA); Taruna Arora (Palo Alto, CA); Hugo Matern (San Mateo, CA); Wenyan Shen (Redwood City, CA)
Assignee:
NGM Biopharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides binding proteins, such as antibodies or binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use such as in producing an antibody or binding fragment thereof. The present disclosure also provides vectors and cells comprising polynucleotides encoding antibodies or binding fragments thereof that bind beta klotho, including human beta klotho.
Claims (35)
1. An isolated polynucleotide or polynucleotides encoding an antibody or binding fragment thereof that binds human beta klotho, wherein the antibody or binding fragment thereof comprises
a heavy chain variable region (VH) comprising a VH complementarity determining region (CDR)1, a VH CDR2, and a VH CDR3 from the amino acid sequence of SEQ ID NO:271; and
a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the amino acid sequence of SEQ ID NO:276.
2. The isolated polynucleotide or polynucleotides of claim 1 , wherein:
(a) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:1, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:2, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6;
(b) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:7, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:8, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:9, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:10, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:11, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6;
(c) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:12, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:2, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6;
(d) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:13, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:14, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:15, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:16, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 11, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17;
(e) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:18, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:19, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:20, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:21, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:22, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:23; or
(f) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:1, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:24, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6.
3. The isolated polynucleotide or polynucleotides of claim 1 , wherein:
the VH CDR1 comprises the amino acid sequence of SEQ ID NO:12, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:2, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6.
4. The isolated polynucleotide or polynucleotides of claim 1 , wherein
the VH comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:271 and the VL comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:276.
5. The isolated polynucleotide or polynucleotides of claim 1 , wherein
the VH comprises the amino acid sequence of SEQ ID NO:271 and the VL comprises the amino acid sequence of SEQ ID NO:276.
6. A vector or vectors comprising the isolated polynucleotide or polynucleotides of claim 5 .
7. A cell comprising the vector or vectors of claim 6 .
8. A method of producing an antibody or binding fragment thereof, the method comprising: (i) culturing the cell of claim 7 ; and (ii) isolating the antibody or binding fragment thereof.
9. The method of claim 8 , wherein the method further comprises formulating the antibody or binding fragment thereof as a sterile pharmaceutical formulation.
10. A cell comprising the isolated polynucleotide or polynucleotides of claim 5 .
11. The isolated polynucleotide or polynucleotides of claim 1 , wherein the antibody or binding fragment thereof is a humanized antibody.
12. The isolated polynucleotide or polynucleotides of claim 1 , wherein the antibody is a human IgG1 antibody, a human IgG2 antibody, or a human IgG4 antibody.
13. A vector or vectors comprising the isolated polynucleotide or polynucleotides of claim 1 .
14. A cell comprising the vector or vectors of claim 13 .
15. A method of producing an antibody or binding fragment thereof, the method comprising: (i) culturing the cell of claim 14 ; and (ii) isolating the antibody or binding fragment thereof.
16. The method of claim 15 , wherein the method further comprises formulating the antibody or binding fragment thereof as a sterile pharmaceutical formulation.
17. A cell comprising the isolated polynucleotide or polynucleotides of claim 1 .
18. An isolated polynucleotide or polynucleotides encoding an antibody that binds human beta klotho, wherein
the antibody comprises a heavy chain comprising amino acids 23-472 of SEQ ID NO:317 and a light chain comprising amino acids 23-240 of SEQ ID NO:319.
19. A vector or vectors comprising the isolated polynucleotide or polynucleotides of claim 18 .
20. A cell comprising the vector or vectors of claim 19 .
21. A method of producing an antibody, the method comprising: (i) culturing the cell of claim 20 ; and (ii) isolating the antibody.
22. The method of claim 21 , wherein the method further comprises formulating the antibody as a sterile pharmaceutical formulation.
23. A cell comprising the isolated polynucleotide or polynucleotides of claim 18 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 10, 2023
From: MONDAL, KALYANI; LI, BETTY CHAN; CHEN, YU; ARORA, TARUNA; MATERN, HUGO; SHEN, WENYAN
To: NGM BIOPHARMACEUTICALS, INC.
Reel/Frame 062703/0211 →
Continuity (6)
Provisional Application
61931531
· Jan 24, 2014
References Cited (387)
US 6579850B1
· Nabeshima
· 2003
[cited by applicant]
US 6635468B2
· Ashkenazi
· 2003
[cited by applicant]
US 6716626B1
· Itoh
· 2004
[cited by applicant]
US 6806352B2
· Desnoyers
· 2004
[cited by applicant]
US 6812339B1
· Venter
· 2004
[cited by applicant]
US 6987121B2
· Kliewer
· 2006
[cited by applicant]
US 7115415B2
· Goddard
· 2006
[cited by applicant]
US 7129072B1
· Schlessinger
· 2006
[cited by applicant]
US 7208312B1
· Desnoyers
· 2007
[cited by applicant]
US 7259248B2
· Itoh
· 2007
[cited by applicant]
US 7288406B2
· Bogin
· 2007
[cited by applicant]
US 7390879B2
· Ashkenazi
· 2008
[cited by applicant]
US 7459540B1
· Thomason
· 2008
[cited by applicant]
US 7491697B2
· Beals
· 2009
[cited by applicant]
US 7537902B2
· Kuro-O
· 2009
[cited by applicant]
US 7576190B2
· Glaesner
· 2009
[cited by applicant]
US 7582607B2
· Frye
· 2009
[cited by applicant]
US 7622445B2
· Frye
· 2009
[cited by applicant]
US 7655627B2
· Frye
· 2010
[cited by applicant]
US 7667005B2
· Nabeshima
· 2010
[cited by applicant]
US 7667008B2
· Thomason
· 2010
[cited by applicant]
US 7705195B2
· French
· 2010
[cited by applicant]
US 7723297B2
· Itoh
· 2010
[cited by applicant]
US 7947866B2
· Sparks
· 2011
[cited by applicant]
US 8012931B2
· Cujec
· 2011
[cited by applicant]
US 8034770B2
· Belouski
· 2011
[cited by applicant]
US 8188040B2
· Belouski
· 2012
[cited by applicant]
US 8324160B2
· Li
· 2012
[cited by applicant]
US 8361963B2
· Belouski
· 2013
[cited by applicant]
US 8372952B2
· Smith
· 2013
[cited by applicant]
US 8383365B2
· Cujec
· 2013
[cited by applicant]
US 8410051B2
· Belouski
· 2013
[cited by applicant]
US 8420088B2
· Glass
· 2013
[cited by applicant]
US 8481031B2
· Glass
· 2013
[cited by applicant]
US 8535912B2
· Sonoda
· 2013
[cited by applicant]
US 8541369B2
· Dickinson
· 2013
[cited by applicant]
US 8580936B2
· Williams
· 2013
[cited by applicant]
US 8618053B2
· Belouski
· 2013
[cited by applicant]
US 8642546B2
· Belouski
· 2014
[cited by applicant]
US 8673860B2
· Schellenberger
· 2014
[cited by applicant]
US 8741841B2
· Darling
· 2014
[cited by applicant]
US 8795985B2
· Belouski
· 2014
[cited by applicant]
US 8802697B2
· Bifulco
· 2014
[cited by applicant]
US 8809499B2
· Fan
· 2014
[cited by applicant]
US 8835385B2
· Belouski
· 2014
[cited by applicant]
US 8883726B2
· Dickinson
· 2014
[cited by applicant]
US 8889426B2
· Mohammadi
· 2014
[cited by applicant]
US 8889621B2
· Mohammadi
· 2014
[cited by applicant]
US 8927492B2
· Darling
· 2015
[cited by applicant]
US 8932589B2
· Glass
· 2015
[cited by applicant]
US 8951966B2
· Ling
· 2015
[cited by applicant]
US 8962557B2
· Blaber
· 2015
[cited by applicant]
US 8975223B2
· Vignati
· 2015
[cited by applicant]
US 8993727B2
· Walker
· 2015
[cited by applicant]
US 8999929B2
· Mohammadi
· 2015
[cited by applicant]
US 9006400B2
· Boettcher
· 2015
[cited by applicant]
US 9089525B1
· Ling
· 2015
[cited by applicant]
US 9273107B2
· Ling
· 2016
[cited by applicant]
US 9290557B2
· Ling
· 2016
[cited by applicant]
US 9580483B2
· Ling
· 2017
[cited by applicant]
US 9670260B2
· Ling
· 2017
[cited by applicant]
US 9738716B2
· Mondal
· 2017
[cited by applicant]
US 9751924B2
· Ling
· 2017
[cited by applicant]
US 9878008B2
· Ling
· 2018
[cited by applicant]
US 9878009B2
· Ling
· 2018
[cited by applicant]
US 9889177B2
· Ling
· 2018
[cited by applicant]
US 9889178B2
· Ling
· 2018
[cited by applicant]
US 9895416B2
· Ling
· 2018
[cited by applicant]
US 9925242B2
· Ling
· 2018
[cited by applicant]
US 20020012961A1
· Botstein
· 2002
[cited by applicant]
US 20020042367A1
· Stewart
· 2002
[cited by applicant]
US 20020082205A1
· Itoh
· 2002
[cited by applicant]
US 20020151496A1
· Bringmann
· 2002
[cited by applicant]
US 20020155543A1
· Adams
· 2002
[cited by applicant]
US 20030045489A1
· Murphy
· 2003
[cited by applicant]
US 20030065140A1
· Vernet
· 2003
[cited by applicant]
US 20030105302A1
· Itoh
· 2003
[cited by applicant]
US 20030113718A1
· Ashkenazi
· 2003
[cited by applicant]
US 20030119112A1
· Baker
· 2003
[cited by applicant]
US 20030125521A1
· Baker
· 2003
[cited by applicant]
US 20030166051A1
· Desnoyers
· 2003
[cited by applicant]
US 20030170822A1
· Itoh
· 2003
[cited by applicant]
US 20030180890A1
· Conklin
· 2003
[cited by applicant]
US 20030185846A1
· Ashkenazi
· 2003
[cited by applicant]
US 20030220246A1
· Conklin
· 2003
[cited by applicant]
US 20040126852A1
· Stewart
· 2004
[cited by applicant]
US 20040146908A1
· Adams
· 2004
[cited by applicant]
US 20040185494A1
· Itoh
· 2004
[cited by applicant]
US 20050026243A1
· Stewart
· 2005
[cited by applicant]
US 20050026832A1
· Adams
· 2005
[cited by applicant]
US 20050107475A1
· Jones
· 2005
[cited by applicant]
US 20050153305A1
· Vernet
· 2005
[cited by applicant]
US 20050181375A1
· Aziz
· 2005
[cited by applicant]
US 20050196842A1
· Botstein
· 2005
[cited by applicant]
US 20060160181A1
· Luethy
· 2006
[cited by applicant]
US 20060172386A1
· Itoh
· 2006
[cited by applicant]
US 20060246540A1
· Ashkenazi
· 2006
[cited by applicant]
US 20060275794A1
· Carrino
· 2006
[cited by applicant]
US 20060281679A1
· Itoh
· 2006
[cited by applicant]
US 20070037165A1
· Venter
· 2007
[cited by applicant]
US 20070042395A1
· Botstein
· 2007
[cited by applicant]
US 20070077626A1
· Botstein
· 2007
[cited by applicant]
US 20070253966A1
· Glaesner
· 2007
[cited by applicant]
US 20080057076A1
· Bringmann
· 2008
[cited by applicant]
US 20080124759A1
· Conklin
· 2008
[cited by applicant]
US 20090081658A1
· Belouchi
· 2009
[cited by applicant]
US 20090098603A1
· Botstein
· 2009
[cited by applicant]
US 20090226459A1
· Powers
· 2009
[cited by applicant]
US 20090312265A1
· Schmidtchen
· 2009
[cited by applicant]
US 20100158914A1
· Desnoyers
· 2010
[cited by applicant]
US 20100330062A1
· Koeffler
· 2010
[cited by applicant]
US 20110015345A1
· Pinkstaff
· 2011
[cited by applicant]
US 20110053787A1
· Brulliard
· 2011
[cited by applicant]
US 20110107439A1
· De Wit
· 2011
[cited by applicant]
US 20110150903A1
· Baurin
· 2011
[cited by applicant]
US 20110195077A1
· Glass
· 2011
[cited by applicant]
US 20110207912A1
· Botstein
· 2011
[cited by applicant]
US 20110312881A1
· Silverman
· 2011
[cited by applicant]
US 20130116171A1
· Jonker
· 2013
[cited by applicant]
US 20130143796A1
· Li
· 2013
[cited by applicant]
US 20130183294A1
· Pai
· 2013
[cited by applicant]
US 20140094406A1
· Mohammadi
· 2014
[cited by applicant]
US 20140148388A1
· Sonoda
· 2014
[cited by applicant]
US 20140189893A1
· Li
· 2014
[cited by applicant]
US 20140363435A1
· Desnoyers
· 2014
[cited by applicant]
US 20160168222A1
· Ling
· 2016
[cited by applicant]
US 20160200788A1
· Ling
· 2016
[cited by applicant]
CN 102858802A
· 2013
[cited by applicant]
DE 10100588
· 2002
[cited by applicant]
DE 10100587
· 2002
[cited by applicant]
EP 2163626A1
· 2010
[cited by applicant]
EP 2510009B1
· 2017
[cited by applicant]
JP 2001072607A
· 2001
[cited by applicant]
JP 2002112772A
· 2002
[cited by applicant]
JP 2003334088A
· 2003
[cited by applicant]
JP 2006158339A
· 2006
[cited by applicant]
JP 2006240990A
· 2006
[cited by applicant]
JP 2009039117A
· 2009
[cited by applicant]
JP 2013194049A
· 2013
[cited by applicant]
NZ 602702
· 2014
[cited by applicant]
WO WO1998029544
· 1998
[cited by applicant]
WO WO2000060085
· 2000
[cited by applicant]
WO WO2001018209A1
· 2001
[cited by applicant]
WO WO2001038529A1
· 2001
[cited by applicant]
WO WO2001049740A1
· 2001
[cited by applicant]
WO WO2001049849A1
· 2001
[cited by applicant]
WO WO2001061007A2
· 2001
[cited by applicant]
WO WO2002036732A2
· 2002
[cited by applicant]
WO WO2002041911A2
· 2002
[cited by applicant]
WO WO2002055693A2
· 2002
[cited by applicant]
WO WO2003080803A2
· 2003
[cited by applicant]
WO WO2004026228A2
· 2004
[cited by applicant]
WO WO2004063355A2
· 2004
[cited by applicant]
WO WO2006004076A1
· 2006
[cited by applicant]
WO WO2006048291A2
· 2006
[cited by applicant]
WO WO2006049854A2
· 2006
[cited by applicant]
WO WO2008021196A2
· 2008
[cited by applicant]
WO WO2008030273A2
· 2008
[cited by applicant]
WO WO2008123625A1
· 2008
[cited by applicant]
WO WO2008135993A1
· 2008
[cited by applicant]
WO WO2009009173A2
· 2009
[cited by applicant]
WO WO2009076478A2
· 2009
[cited by applicant]
WO WO2009090553A2
· 2009
[cited by applicant]
WO WO2009095372A1
· 2009
[cited by applicant]
WO WO2009116861A2
· 2009
[cited by applicant]
WO WO2010004204A2
· 2010
[cited by applicant]
WO WO2010006214A1
· 2010
[cited by applicant]
WO WO2010042747A2
· 2010
[cited by applicant]
WO WO2010065439A1
· 2010
[cited by applicant]
WO WO2010080976A1
· 2010
[cited by applicant]
WO WO2010083051A2
· 2010
[cited by applicant]
WO WO2010129600A2
· 2010
[cited by applicant]
WO WO2010139741A1
· 2010
[cited by applicant]
WO WO2010142665A1
· 2010
[cited by applicant]
WO WO2010148142A1
· 2010
[cited by applicant]
WO WO2011047267A1
· 2011
[cited by applicant]
WO WO2011068893A1
· 2011
[cited by applicant]
WO WO2011071783A1
· 2011
[cited by applicant]
WO WO2011084808A2
· 2011
[cited by applicant]
WO WO2011089203A1
· 2011
[cited by applicant]
WO WO2011092234A1
· 2011
[cited by applicant]
WO WO2011130417A2
· 2011
[cited by applicant]
WO WO2011130729A2
· 2011
[cited by applicant]
WO WO2011154349A2
· 2011
[cited by applicant]
WO WO2012010553A1
· 2012
[cited by applicant]
WO WO2012031603A2
· 2012
[cited by applicant]
WO WO2012062078A1
· 2012
[cited by applicant]
WO WO2012066075A1
· 2012
[cited by applicant]
WO WO2012086809A1
· 2012
[cited by applicant]
WO WO2012138919A2
· 2012
[cited by applicant]
WO WO2012140650A2
· 2012
[cited by applicant]
WO WO2012154263A1
· 2012
[cited by applicant]
WO WO2012158704A1
· 2012
[cited by applicant]
WO WO2012170438A2
· 2012
[cited by applicant]
WO WO2012170704A2
· 2012
[cited by applicant]
WO WO2012177481A2
· 2012
[cited by applicant]
WO WO2013006486A2
· 2013
[cited by applicant]
WO WO2013010780A1
· 2013
[cited by applicant]
WO WO2013027191A1
· 2013
[cited by applicant]
WO WO2013033452A2
· 2013
[cited by applicant]
WO WO2013049234A2
· 2013
[cited by applicant]
WO WO2013109856A2
· 2013
[cited by applicant]
WO WO2013131091A1
· 2013
[cited by applicant]
WO WO2013151671A1
· 2013
[cited by applicant]
WO WO2013173158A1
· 2013
[cited by applicant]
WO WO2013184958A1
· 2013
[cited by applicant]
WO WO2013184960A2
· 2013
[cited by applicant]
WO WO2013184962A1
· 2013
[cited by applicant]
WO WO2013188182A1
· 2013
[cited by applicant]
WO WO2014031420A1
· 2014
[cited by applicant]
WO WO2014037373A1
· 2014
[cited by applicant]
WO WO2014085365A2
· 2014
[cited by applicant]
WO WO2014105939A1
· 2014
[cited by applicant]
WO WO2014130659A1
· 2014
[cited by applicant]
WO WO2014149699A1
· 2014
[cited by applicant]
WO WO2014152090A1
· 2014
[cited by applicant]
WO WO2015065897A1
· 2015
[cited by applicant]
WO WO2015100366A1
· 2015
[cited by applicant]
WO WO2015112886A2
· 2015
[cited by applicant]
WO WO2015183890A2
· 2015
[cited by applicant]
WO WO2015195509A2
· 2015
[cited by applicant]
WO WO2016065106A1
· 2016
[cited by applicant]
WO WO2016073855A1
· 2016
[cited by applicant]
WO WO2017083276A1
· 2017
[cited by applicant]
WO WO2018039557A1
· 2018
[cited by applicant]
WO WO2018044778A1
· 2018
[cited by applicant]
Adams et al., “FGF21 requires βklotho to act in vivo, ” PloS One, 2012, 7(11):e49977.
[cited by applicant]
Aranha et al., “Bile acid levels are increased in the liver of patients with steatohepatitis,” Eur. J. Gastroenterol. Hepatol., 2008, 20(6):519-525.
[cited by applicant]
Beenken et al., “The FGF family: biology, pathophysiology and therapy,” Nat. Rev. Drug Discov., 2009, 8:235-253.
[cited by applicant]
Beuers et al., “Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-) transcriptional modulators?,” Clin. Rev. Allergy Immunol., 2009, 36(1):52-61.
[cited by applicant]
Bromberg et al., “Stat3 as an oncogene,” Cell, 1999, 98:295-303.
[cited by applicant]
Calvisi et al., “Ubiquitous activation of Ras and Jak/Stat pathways in human HCC,” Gastroenterol., 2006, 130:1117-1128.
[cited by applicant]
Camilleri et al., “Measurement of Serum 7α-hydroxy-4-cholesten-3-one (or 7αC4), a Surrogate Test for Bile Acid Malabsorption in Health, Ileal Disease and Irritable Bowel Syndrome using Liquid Chromatography-Tandom Mass …
[cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem. Biophys. Res. Commun., 2003, 307:198-205.
[cited by applicant]
Chazouilleres, “Primary sclerosing cholangitis and bile acids,” Clinics and Research in Hepatology and Gastroenterology, 2012, 36:S21-S25.
[cited by applicant]
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” J. Mol. Biol., 1999, 293:865-881.
[cited by applicant]
Chen et al., “Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease,” Biochem. Biophys. Res. Comm., 2011, 409:651-656.
[cited by applicant]
Chen et al., “Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3,” Clin. Cancer Res., 2010, 16:5189-5199.
[cited by applicant]
Claudel et al., “Role of Nuclear Receptors for Bile Acid Metabolism, Bile Secretion, Cholestasis, and Gallstone Disease,” Biochim. Biophys. Acta, 2011, 1812:867-878.
[cited by applicant]
Davidson et al., “A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes,” Immunology, Sep. 2014, 143(1):13-20.
[cited by applicant]
De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” …
[cited by applicant]
Desnoyers et al., “Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models,” Oncogene, 2008, 27:85-97.
[cited by applicant]
Ďurovcová et al., “Plasma Concentration of Fibroblast Growth Factors 21 and 19 in Patients with Cushing's Syndrome,” Physiol. Res., 2010, 59:415-422.
[cited by applicant]
Foltz et al., “Supplementary Materials For: Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR 1c Receptor Complex,” Sci. Transl. Med., 2012, 4:162ra153, 1-13.
[cited by applicant]
Foltz et al., “Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFRIc Receptor Complex,” Sci. Transl. Med., 2012, 4(162):1-10.
[cited by applicant]
French et al., “Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models,” PLoS One, 2012, 7(5):e36713, 1-12.
[cited by applicant]
Fukumoto et al., “FGF23 is a hormone-regulating phosphate metabolism—unique biological characteristics of FGF23,” Bone, 2007, 40(5):1190-1195.
[cited by applicant]
Ge et al., “Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism,” PLoS One, 2012, 7(3):e33603, 1-9.
[cited by applicant]
GenBank EHH53620.1: Beta-klotho (Macaca fascicularis)[online] Nov. 4, 2011 [retrieved Mar. 28, 2015]. Available on the internet: < URL: //www.ncbi.nlm.nih.gov/protein/355749221?sat-=37&satkey=109028311>, 2 pages.
[cited by applicant]
Goetz et al., “Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members,” Mol. Cell. Biol., 2007, 27(9):3417-3428.
[cited by applicant]
Harmer et al., “The Crystal Structure of Fibroblast Growth Factor (FGF) 19 Reveals Novel Features of the FGF Family and Offers a Structural Basis for Its Unusual Receptor Affinity,” Biochemistry, 2004, 43:629-640.
[cited by applicant]
Hasegawa, “The expansion of PROMININ-1-positive epithelial-mesenchymal cells within periportal fibrosis of rotavirus induced biliary atresia,” Hepatol., 2013, 58:802A.
[cited by applicant]
He et al., “Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation,” Cancer Cell, 2010, 17:286-297.
[cited by applicant]
He et al., “Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling,” Cell, 2013, 155:384-396.
[cited by applicant]
He et al., “NF-κB and STAT3—key players in liver inflammation and cancer,” Cell Res., 2011, 21:159-168.
[cited by applicant]
Hofmann et al., “Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: A new syndrome of defective FGF19 release,” Clin. Gastroenterol. Hepatol., 2009, 7(11):1151-1154.
[cited by applicant]
Holm et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Mol. Immunol., 2007, 44:1075-1084.
[cited by applicant]
Holt et al., “Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis,” Genes Dev., 2003, 17:1581-1591.
[cited by applicant]
Ikeda et al., “Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma,” Gastroenterol., 2014, 146:222-232.
[cited by applicant]
Inagaki et al., “Fibroblast Growth Factor 15 Functions as an Enterohepatic Signal to Regulate Bile Acid Homeostasis,” Cell Metabolism, 2005, 2:217-225.
[cited by applicant]
Ito et al., “Molecular cloning and expression analyses of mouse beta klotho, which encodes a novel Klotho family protein,” Mech. Dev., 2000, 98(1-2):115-119.
[cited by applicant]
Kakumu et al., “Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis,” Gastroenterologia Japonica, 1993, 28:18-24.
[cited by applicant]
Karras et al., “STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression,” Cellular Immunol., 2000, 202:124-135.
[cited by applicant]
Kenakin et al., “Signalling bias in new drug discovery: detection, quantification and therapeutic impact,” Nat. Rev. Drug Discov., 2013, 12:205-216.
[cited by applicant]
Kir et al., “Roles of FGF19 in Liver Metabolism,” Cold Spring Harb. Symp. Quant. Biol., 2011, 76:139-144.
[cited by applicant]
Kumar et al., “Molecular cloning and expression of the Fabs of human autoantibodies in
[cited by applicant]
KURO-O;
[cited by applicant]
Kurosu et al., “Regulation of fibroblast growth factor-23 signaling by klotho,” J. Biol. Chem., 2006, 281(10):6120-6123.
[cited by applicant]
Kurosu et al., “Supplemental Data For: Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21,” J. Biol. Chem., (2007) (available at: …
[cited by applicant]
Kurosu et al., “Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21,” J. Biol. Chem., 2007, 282(37):26687-26695.
[cited by applicant]
Lee et al., “Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signaling,” Nature, 2018, 553:501-505, Extended Data.
[cited by applicant]
Lin et al., “Liver-specific Activities of FGF19 Require Klotho beta,” J. Biol. Chem., 2007, 282(37):27277-27284.
[cited by applicant]
Lin et al., “The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling,” Oncogene, 2009, 28:961-972.
[cited by applicant]
Lindor, “Ursodeoxycholic acid for the treatment of primary biliary cirrhosis,” New Engl. J Med., 2007, 357:1524-1529.
[cited by applicant]
Ling et al., “Identification of Gut Factors that Mimic the Metabolic Benefits Seen After Gastric Bypass Surgery,” American Diabetes Association, 72nd Scientific Sessions, Jun. 8-12, 2012, Philadelphia, PA, http://www.ab…
[cited by applicant]
Ling et al., NGM Biopharmaceuticals, Identification of Gut Factors that Mimic the Metabolic Benefits of Gastric Bypass Surgery, p. 1, Jun. 8-12, 2012, Abstract.
[cited by applicant]
Luo et al., “A nontumorigenic variant of FGF19 treats cholestatic liver diseases,” Sci. Transl. Med., 2014, 6:247ra100, 1-11.
[cited by applicant]
Maccallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol.Biol., 1996, 262:732-745.
[cited by applicant]
Mellor, “Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations,” Liver Int., 2014, e1-e9.
[cited by applicant]
Micanovic et al., “Different roles of N- and C-termini in the functional activity of FGF21,” J. Cell. Physiol., 2009, 219:227-234.
[cited by applicant]
Miyata et al., “Involvement of Multiple Elements in FXR-mediated Transcriptional Activation of FGF19,” J. Steroid Biochm. Mol. Biol., 2012, 132:41-47.
[cited by applicant]
Moyers et al., “Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling,” J. Cell. Physiol., 2007, 210(1):1-6.
[cited by applicant]
NCBI Reference Sequence: NP_783864.1: beta-klotho (
[cited by applicant]
Nicholes et al., “A Mouse Model of Hepatocellular Carcinoma: Ectopic Expression of Fibroblast Growth Factor in Skeletal Muscle of Transgenic Mice,” Amer. J. Pathol., 2002, 160:2295-2307.
[cited by applicant]
Ogawa et al., “Beta Klotho is Required for Metabolic Activity of Fibroblast Growth Factor 21,” Proc. Natl. Acad. Sci. USA, 2007, 104:7432-7437.
[cited by applicant]
Pai et al., “Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys,” Toxicological Sciences, 2012, 126(2):446-4…
[cited by applicant]
Pattni et al., “Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea,” Clinical and Translational Gastroenterology, 2012, 3:e18, 7 pages.
[cited by applicant]
Potthoff et al., “Endocrine Fibroblast Growth Factors 15/19 and 21: From Feast to Famine,” Genes Dev., 2012, 26:312-324.
[cited by applicant]
Pusl et al., “Intrahepatic cholestasis of pregnancy,” Orphanet. J Rare Diseases, 2007, 2:26.
[cited by applicant]
R&D Systems, “Monoclonal Anti-human/mouse Klotho β Antibody,” catalog No. MAB3738, Feb. 6, 2007, 1 page.
[cited by applicant]
Rose et al., “Molecular Control of Systemic Bile Acid Homeostasis by the Liver Glucocorticoid Receptor,” Cell Metabolism, 2011, 14:123-130.
[cited by applicant]
Rossi et al., “Ngm282, a Novel Specific Inhibitor of Cyp7a1-Mediated Bile Acid Synthesis, is Safe and Well Tolerated with Predictable Pharmacokinetics in Healthy Human Subjects,” Journal of Hepatology, 2014, 60(1): S533.
[cited by applicant]
Ryan et al., “FXR is a Molecular Target for the Effects of Vertical Sleeve Gastroectomy,” Nature, 509(7499):183-188, 2014, epub ahead of print Mar. 26, 2014.
[cited by applicant]
Sawey et al., “Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening,” Cancer Cell, 2011, 19(3):347-358.
[cited by applicant]
Schaap et al., “High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis,” Hepatol., 2009, 49:1228-1235.
[cited by applicant]
Schaap, “Role of Fibroblast Growth Factor 19 in the Control of Glucose Homeostasis,” Curr. Opin. Clin. Nutr. Metab. Care, 2012, 15(4):386-391.
[cited by applicant]
Smith et al., “FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR 1c/b-Klotho Bispecific Protein,” PLoS One, 2013, 8(4):1-11.
[cited by applicant]
Smith-Gill et al., “Contributions of Immunoglobulin Heavy and Light Chains to Antibody Specificity for Lysozyme and Two Haptens,” J. Immunol., 1987, 139:4135-4144.
[cited by applicant]
Song et al., “Light Chain of Natural Antibody Plays a Dominant Role in Protein Antigen Binding,” Biochem. Biophys. Res. Comm., 2000, 268:390-394.
[cited by applicant]
Tartaglia et al., “Identification and expression cloning of a leptin receptor, Ob-R,” Cell, 1995, 83:1263-1271.
[cited by applicant]
Tomlinson et al., “Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity,” Endocrinology, 2002, 143(5):1741-1747.
[cited by applicant]
Urakawa et al., “Klotho converts canonical FGF receptor into a specific receptor for FGF23,” Nature, 2006, 444(7210):770-774.
[cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 2002, 320:415-428.
[cited by applicant]
Walters et al., “Managing bile acid diarrhoea,” Ther. Adv. Gastroenterol., 2010, 3(6):349-357.
[cited by applicant]
Walters, “A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism,” Ann. Transl. Med., 2015, 3(S1):S7.
[cited by applicant]
Wang et al., “Leptin in hepatocellular carcinoma,” World J. Gastroenterol., 2010, 16:5801-5809.
[cited by applicant]
Wu et al., “FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways,” PLoS One, 2011, 6(3):e17868, 1-11.
[cited by applicant]
Wu et al., “C-terminal Tail of FGF19 Determines Its Specificity toward Klotho C-receptors,” J. Biol. Chem., 2008, 283(48):33304-33309.
[cited by applicant]
Wu et al., “FGF19-induced Hepatocyte Proliferation is Mediated Through FGFR4 Activation,” J. Biol. Chem., 2010, 285(8):5165-5170.
[cited by applicant]
Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J. Mol. Biol., 1999, 294:151-162.
[cited by applicant]
Wu et al., “Role of FGF19 Induced FGFR4 Activation in the Regulation of Glucose Homeostasis,” Aging, 2009, 1(12):1023-1027.
[cited by applicant]
Wu et al., “Selective Activation of FGFR4 by an FGF19 Variant Does Not Improve Glucose Metabolism in ob/ob Mice,” Proc. Natl. Acad. Sci. USA, 2009, 106(34):14379-14384.
[cited by applicant]
Wu et al., “Separating Mitogenic and Metabolic Activities of Fibroblast Growth Factor 19 (FGF19),” Proc. Natl. Acad. Sci. USA, 2010, 107(32):14158-14163.
[cited by applicant]
Wu et al., “Therapeutic Utilities of Fibroblast Growth Factor 19,” Expert Opin. Ther. Targets, 2011, 15(11):1307-1316.
[cited by applicant]
Xie et al., “FGF-19, A Novel Fibroblast Growth Factor with Unique Specificity for FGFR4,” Cytokine, 1999, 11(10):729-735.
[cited by applicant]
Zhang et al., “Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production,” Hum. Gene Ther., 2009, 20:922-929.
[cited by applicant]
Zhang et al., “Fibroblast growth factor 21 analogs for treating metabolic disorders,” Front. Endocrinol., 2015, 6(168):1-9.
[cited by applicant]
Zhou et al., “Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice,” Hepatology, 2016, 63(3):914-929.
[cited by applicant]
Zhou et al., “Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19,” Cancer Research, 2014, 74(12):3306-3316.
[cited by applicant]